Omeros
Open
$8.78
Prev. Close
$8.78
High
$8.83
Low
$8.73
Market Snapshot
$628.89M
7.3
-2.71
175
Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. The company is headquartered in Seattle, Washington and currently employs 175 full-time employees. The company went IPO on 2009-10-08. The firm is focused on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan diseases, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The firm's lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before the FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in phase I single- and multiple-ascending-dose clinical studies. Its lead phosphodiesterase 7 (PDE7) inhibitor, OMS527, is in clinical development for the treatment of cocaine use disorders. The firm also has preclinical programs, including an oncology platform for the development of novel therapeutics.
Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. The company is headquartered in Seattle, Washington and currently employs 175 full-time employees. The company went IPO on 2009-10-08. The firm is focused on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan diseases, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The firm's lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before the FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in phase I single- and multiple-ascending-dose clinical studies. Its lead phosphodiesterase 7 (PDE7) inhibitor, OMS527, is in clinical development for the treatment of cocaine use disorders. The firm also has preclinical programs, including an oncology platform for the development of novel therapeutics.
Recently from Cashu
Omeros Reports Strong Initial Sales for YARTEMLEA, Indicating Promising Future Growth
Omeros Corporation (Ticker: OMER) shows strong initial performance for its recently launched drug YARTEMLEA, indicating a promising trajectory for the company. In its Q1 2026 earnings report, Omeros a…
Update on Omeros: Recent Developments and Industry Insights
It appears that there is no specific content provided for me to summarize. If you could share the text or details about Omeros or relevant developments in the industry, I'd be glad to assist in creati…
Omeros Advances Therapeutics Amid Economic Uncertainty and Promotes Non-Opioid Pain Management
Omeros Advances in Therapeutic Development Amid Economic Uncertainty Omeros Corporation makes significant strides in the biopharmaceutical sector as it focuses on advancing its therapeutic pipeline. T…
Omeros Corporation Secures FDA Approval for Yartemlea to Treat TA-TMA
Omeros Corporation Gains FDA Approval for Yartemlea: A Breakthrough in Treating TA-TMA Omeros Corporation achieves a significant milestone with the U.S. Food and Drug Administration's (FDA) approval o…